What Researchers Did
Researchers investigated an innovative approach combining hyperbaric oxygen therapy with hypofractionated stereotactic radiotherapy to treat nine adult patients with recurrent high-grade glioma.
What They Found
After a median follow-up of 11.6 months, 55.5% of patients showed disease control three months after receiving radiation therapy within 60 minutes of hyperbaric oxygen. The median time patients lived without their disease getting worse was 5.2 months, and their median overall survival was 10.7 months. Notably, 88.88% of patients experienced no significant neurological side effects, with one patient developing severe radionecrosis.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
This study was an interim analysis conducted on a small preliminary group of only nine patients, limiting the generalizability of the findings.